IPO
Explore our secure online trading, IPO bidding, mutual fund investments, and depository services, all designed to provide seamless transactions, expert insights, and real-time market access for smart investing
Windlas Biotech Ltd
Windlas Biotech Ltd
Registered Office : 40/1 Mohabewala Industrial,Area,Dehradun Uttarakhand 248110 Phone : 91-135-6608000
Fax :
Email : grievance@windlasbiotech.com
Website : www.windlasbiotech.com
Initial Public Offer of 8,729,023* equity shares of face value of Rs.5 each ("equity shares") of Windlas Biotech Limited ("company" Rs.455 per equity share) aggregating to Rs.401.54 Crores (the "offer") comprising a fresh issue of 3,586,956* equity shares aggregating to Rs.165 Crores (the "fresh issue") and an offer for sale of 5,142,067* equity shares, comprising of 1,136,000* equity shares aggregating to Rs.52.26* Crores by Vimla Windlass (the "individual selling shareholder") and 4,006,067* equity shares aggregating to Rs.184.28* Crores by Tano India Private Equity Fund II (the "investor selling shareholder", and collectively with the individual selling shareholder, the "selling shareholders", and such equity shares, the "offered shares") aggregating to Rs.236.54 Crores (the "offer for sale). The offer constitutes 40.05% of the post-offer paid-up equity share capital of the Company. The face value of equity shares is Rs.5 each. The offer price is Rs.460 per equity share and is 92 times the face value of the equity shares. *subject to finalisation of the basis of allotment.
Opens On
Closes On
04-Aug-2021
06-Aug-2021
Application
Allotment
460.00
0.00
Minimum Application for shares in Nos : 30.0 Further Multiples of : 30.0
₹Cr
Lead Managers to the Issue
Project Cost (₹.Cr)
Project Financed through Current Offer (₹.Cr)
Post Issue Equity Share Capital (₹.Cr)
Issue Price (₹.Cr)
165.00
401.54
10.90
460.00
DAM Capital Advisors Ltd
IIFL Securities Ltd
SBI Capital Markets Ltd
- Purchase of Equipment required for (i) Capacity Expansion of the existing facility at the Dehradun Plant-IV and (II) Addition of Injectables Dosage Capability at the existing facility at Dehradun Plant - II
- Funding Incremental Working Capital Requirements of the Company
- Repayment/Prepayment of certain of the Borrowings
- General Corporate Purposes
- Ashok Kumar Windlass
- Hitesh Windlass
- Manoj Kumar Windlass
- BSE
- NSE
- MUFG Intime India Pvt Ltd